358 related articles for article (PubMed ID: 12949887)
1. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
Nielsen I; Hasselbalch HC
Am J Hematol; 2003 Sep; 74(1):26-31. PubMed ID: 12949887
[TBL] [Abstract][Full Text] [Related]
2. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
3. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders.
Randi ML; Ruzzon E; Luzzatto G; Tezza F; Girolami A; Fabris F
Haematologica; 2005 Feb; 90(2):261-2. PubMed ID: 15710584
[TBL] [Abstract][Full Text] [Related]
4. [Hydroxyurea-induced leg ulcers in patients with chronic myeloproliferative disorders].
Olesen LH; Pedersen BB
Ugeskr Laeger; 2001 Dec; 163(49):6908-11. PubMed ID: 11766504
[TBL] [Abstract][Full Text] [Related]
5. Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature.
Swolin B; Rödjer S; Westin J
Ann Hematol; 2008 Jun; 87(6):467-74. PubMed ID: 18351338
[TBL] [Abstract][Full Text] [Related]
6. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.
Sterkers Y; Preudhomme C; Laï JL; Demory JL; Caulier MT; Wattel E; Bordessoule D; Bauters F; Fenaux P
Blood; 1998 Jan; 91(2):616-22. PubMed ID: 9427717
[TBL] [Abstract][Full Text] [Related]
7. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
[TBL] [Abstract][Full Text] [Related]
8. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.
Kiladjian JJ; Chevret S; Dosquet C; Chomienne C; Rain JD
J Clin Oncol; 2011 Oct; 29(29):3907-13. PubMed ID: 21911721
[TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea.
Bernasconi P; Boni M; Cavigliano PM; Calatroni S; Brusamolino E; Passamonti F; Volpe G; Pistorio A; Giardini I; Rocca B; Caresana M; Lazzarino M; Bernasconi C
Leukemia; 2002 Oct; 16(10):2078-83. PubMed ID: 12357360
[TBL] [Abstract][Full Text] [Related]
10. Treatment paradigms in the management of myeloproliferative disorders.
Fruchtman SM
Semin Hematol; 2004 Apr; 41(2 Suppl 3):18-22. PubMed ID: 15190519
[TBL] [Abstract][Full Text] [Related]
11. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983-99.
Johansson P; Kutti J; Andréasson B; Safai-Kutti S; Vilén L; Wedel H; Ridell B
J Intern Med; 2004 Aug; 256(2):161-5. PubMed ID: 15257729
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.
Hasselbalch HC; Bjerrum OW; Jensen BA; Clausen NT; Hansen PB; Birgens H; Therkildsen MH; Ralfkiaer E
Am J Hematol; 2003 Dec; 74(4):238-42. PubMed ID: 14635203
[TBL] [Abstract][Full Text] [Related]
13. Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease.
Löfvenberg E; Nordenson I; Wahlin A
Cancer Genet Cytogenet; 1990 Oct; 49(1):57-67. PubMed ID: 2397474
[TBL] [Abstract][Full Text] [Related]
14. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England.
Phekoo KJ; Richards MA; Møller H; Schey SA;
Haematologica; 2006 Oct; 91(10):1400-4. PubMed ID: 17018393
[TBL] [Abstract][Full Text] [Related]
15. Toxicity and side effects of hydroxyurea used for primary thrombocythemia.
Randi ML; Ruzzon E; Tezza F; Luzzatto G; Fabris F
Platelets; 2005; 16(3-4):181-4. PubMed ID: 16011962
[TBL] [Abstract][Full Text] [Related]
16. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
[TBL] [Abstract][Full Text] [Related]
17. Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.
Randi ML; Fabris F; Girolami A
Leuk Lymphoma; 2000 Apr; 37(3-4):379-85. PubMed ID: 10752989
[TBL] [Abstract][Full Text] [Related]
18. AML transformation in 56 patients with Ph- MPD in two well defined populations.
Abdulkarim K; Girodon F; Johansson P; Maynadié M; Kutti J; Carli PM; Bovet E; Andréasson B
Eur J Haematol; 2009 Feb; 82(2):106-11. PubMed ID: 19134023
[TBL] [Abstract][Full Text] [Related]
19. Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution.
Radaelli F; Onida F; Rossi FG; Zilioli VR; Colombi M; Usardi P; Calori R; Zanella A
Hematology; 2008 Aug; 13(4):195-202. PubMed ID: 18796244
[TBL] [Abstract][Full Text] [Related]
20. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms.
Najfeld V; Cozza A; Berkofsy-Fessler W; Prchal J; Scalise A
Exp Hematol; 2007 Nov; 35(11):1668-76. PubMed ID: 17976519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
